DE69229393D1 - Verfahren zur reinigung von hmg-coa reductase-inhibitoren - Google Patents

Verfahren zur reinigung von hmg-coa reductase-inhibitoren

Info

Publication number
DE69229393D1
DE69229393D1 DE69229393T DE69229393T DE69229393D1 DE 69229393 D1 DE69229393 D1 DE 69229393D1 DE 69229393 T DE69229393 T DE 69229393T DE 69229393 T DE69229393 T DE 69229393T DE 69229393 D1 DE69229393 D1 DE 69229393D1
Authority
DE
Germany
Prior art keywords
coa reductase
reductase inhibitors
hmg
purifying
purifying hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69229393T
Other languages
English (en)
Inventor
Peter Haytko
Arthur Wildman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24683910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69229393(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69229393D1 publication Critical patent/DE69229393D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/322—Normal bonded phase
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69229393T 1991-03-13 1992-03-09 Verfahren zur reinigung von hmg-coa reductase-inhibitoren Expired - Lifetime DE69229393D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/668,831 US5202029A (en) 1991-03-13 1991-03-13 Process for purification of hmg-coa reductase inhibitors
PCT/US1992/001864 WO1992016276A1 (en) 1991-03-13 1992-03-09 PROCESS FOR PURIFICATION OF HMG-CoA REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
DE69229393D1 true DE69229393D1 (de) 1999-07-15

Family

ID=24683910

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69229393T Expired - Lifetime DE69229393D1 (de) 1991-03-13 1992-03-09 Verfahren zur reinigung von hmg-coa reductase-inhibitoren

Country Status (9)

Country Link
US (1) US5202029A (de)
EP (1) EP0578723B1 (de)
JP (1) JPH06506210A (de)
AT (1) ATE180986T1 (de)
CA (1) CA2104232A1 (de)
DE (1) DE69229393D1 (de)
ES (1) ES2132121T3 (de)
GR (1) GR3030446T3 (de)
WO (1) WO1992016276A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308479A (en) * 1989-05-26 1994-05-03 Isamu Iwai Sewage disposal apparatus employing circulating filter media
DE4414537A1 (de) * 1994-04-26 1995-11-02 Klinge Co Chem Pharm Fab Kombinationspräparate mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem HMG-CoA-Reduktase-Hemmer
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20072A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
EP1228057A2 (de) 1999-10-27 2002-08-07 Merck & Co., Inc. Laktonbildungsverfahren
KR20030026920A (ko) * 1999-11-30 2003-04-03 비오갈 기오기스제르갸르 알티. 발효 브로스로부터 스타틴 화합물의 수집 방법
HUP0204005A3 (en) * 1999-12-14 2003-05-28 Teva Gyogyszergyar Zartkoeruee Novel forms of pravastatin sodium, process for their preparation and pharmaceutical compositions containing them
SK12012002A3 (sk) 2000-02-24 2003-02-04 Biogal Gyogyszergyar Rt. Spôsob purifikácie fermentačného bujónu
CZ20023201A3 (cs) 2000-03-03 2003-09-17 Plus Chemicals S. A. Způsob čištění lovastatinu a simvastatinu na produkt se sníženou hladinou dimerních nečistot
EP1192963A4 (de) * 2000-04-05 2004-08-25 Toray Industries Adsorbentien für proteine der gruppe high mobility protein und säule zum reinigen von körperflüssigkeiten
AU2002211462A1 (en) * 2000-10-05 2002-04-22 Teva Gyogyszergyar Reszvenytarsasag Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
US6936731B2 (en) * 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP4037898B2 (ja) * 2003-06-18 2008-01-23 テバ ファーマシューティカル インダストリーズ リミティド フルバスタチンナトリウム結晶形ｘｉｖ、ｌｘｘｉｉｉ、ｌｘｘｉｘ、ｌｘｘｘ及びｘｘｘｖｉｉ型、それらの調製方法、それらを含有する組成物及びそれらの使用方法
US7368468B2 (en) * 2003-06-18 2008-05-06 Teva Pharmaceutical Industries Ltd. Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
CA2546701C (en) * 2003-11-24 2010-07-27 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
TWI319707B (en) 2003-11-24 2010-01-21 Method of purifying pravastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
WO2006035295A1 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for the purification of lovastatin
JP4713574B2 (ja) 2005-02-22 2011-06-29 テバ ファーマシューティカル インダストリーズ リミティド ロスバスタチンアルキルエーテルを含まないロスバスタチンおよびその塩およびそれらを製造する方法
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
US9078849B2 (en) 2009-04-08 2015-07-14 Nanyang Polytechnic Plant extract comprising statins and preparation techniques and uses thereof
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
EP2590722A4 (de) * 2010-07-07 2015-06-24 Ironstone Separations Inc Zeitmessverfahren
EP2597092A1 (de) 2011-11-24 2013-05-29 Sterling Biotech Limited Verfahren zum Reinigen von Lovastatin
CN112657231B (zh) * 2020-12-24 2022-06-10 西安蓝晓科技新材料股份有限公司 一种三七总皂苷的提纯工艺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
JPS58140024A (ja) * 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
US4719229A (en) * 1987-05-13 1988-01-12 Merck & Co., Inc. Antihypercholesterolemic agents
US4778600A (en) * 1987-06-17 1988-10-18 Dow Corning Corporation Liquid chromatography dual zone packing materials
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US5099035A (en) * 1989-02-27 1992-03-24 E. R. Squibb & Sons, Inc. Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same
US5102911A (en) * 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids

Also Published As

Publication number Publication date
JPH06506210A (ja) 1994-07-14
GR3030446T3 (en) 1999-09-30
ES2132121T3 (es) 1999-08-16
CA2104232A1 (en) 1992-09-14
EP0578723A4 (en) 1994-06-22
WO1992016276A1 (en) 1992-10-01
ATE180986T1 (de) 1999-06-15
US5202029A (en) 1993-04-13
EP0578723B1 (de) 1999-06-09
EP0578723A1 (de) 1994-01-19

Similar Documents

Publication Publication Date Title
DE69229393D1 (de) Verfahren zur reinigung von hmg-coa reductase-inhibitoren
DE69321843D1 (de) Verfahren zur entsorgung von stadtmüll
DE69627613D1 (de) Verfahren zur Rückgewinnung von Substraten
BR9506535A (pt) Inibidores de metaloproteinases
DE69310324T3 (de) Verfahren zur Entschwefelung von Kohlenwasserstoffen
DE69508733D1 (de) Verfahren zur Carboxylierung eines Alkohols
DE69421751T2 (de) Verfahren zur Reinigung von Abwässern durch Oxidation auf einen Adsorbentträger
DE69400257D1 (de) Verfahren zur Reinigung von Pentafluorethan
DE69202962D1 (de) Verfahren zur Glycidylierung von Alkoholen.
FI962086A (fi) Faasierotuslaite
DE69314365D1 (de) Verfahren zur Monohydroxylierung von Phenolverbindungen
DE69433634D1 (de) Verfahren zur Umsetzung von Kohlenwasserstoffen
EA199900221A1 (ru) Синтез бисиндолилмалеимидов
DE69415837D1 (de) Verfahren zur Verminderung des freien Aldehydgehaltes von N-Alkylolamidmonomeren
DE69403489D1 (de) Gasphasenverfahren zur epoxidation von nicht-allylischen olefinen
DE69412559T2 (de) Verfahren zur Vergasung von organischen Materien
DE69426979D1 (de) Verfahren zur herstellung von hiv-proteasehemmern
DE69212731D1 (de) Verfahren zur elektro-osmotischen Entwässerung von Schlamm
DE59303043D1 (de) Verfahren zur entsorgung des überschussschlammes
DE69406205D1 (de) Verfahren zur Isomerisierung von Cis-Alkenylverbindungen
DE69221561T2 (de) Verfahren zur Ammoxydation von gesättigten Kohlenwasserstoffen
DK133793D0 (da) Fremgangsmaade til dehydrogenering af carbonhydrider
DE59405678D1 (de) Verfahren zur Reinigung von alkalischem Prozesskondensat-Abwasser
DE59406203D1 (de) Verfahren zur Photooxidation von Terpenolefinen
DE59400815D1 (de) Verfahren zur umweltfreundlichen verwertung von sauren abwässern

Legal Events

Date Code Title Description
8332 No legal effect for de